We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
Read MoreHide Full Article
Agenus Inc. (AGEN - Free Report) incurred loss of 37 cents per share in line with the Zacks Consensus Estimate. The figure came in narrower the year-ago loss of 47 cents.
Revenues of $3.4 million missed the Zacks Consensus Estimate of $4 million. Also, the top line was down from $4.4 million in the year-ago quarter.
So far this year, shares of Agenus have declined 15.1%, as against the industry’s growth of 3.3%.
Quarterly Highlights
Agenus' third-quarter research and development (R&D) expenses were up 19.5% to $25.8 million. However, general and administrative expenses were down slightly by 0.7% to $8.1 million.
Pipeline Update
Agenus is progressing well with various candidates in its pipeline. The company expects to complete phase I dose-escalation, and generate safety and pharmacodynamic data for its anti-CTLA-4 antibody AGEN1884 later in 2017. Also, it is planning to start combination trials of AGEN1884 and AGEN2034 by the year end.
Agenus separate business entity -AgenTus, will help enhance business focus, speed and efficiency towards the realization of breakthrough immuno-oncology drugs designed to cure patients with advanced cancers.
Zacks Rank and Key Picks
Agenus carries a Zacks Rank #2 (Buy).Some other top-ranked health care stocks in the same space include Ligand Pharmaceuticals Inc. (LGND - Free Report) , Exelixis, Inc. (EXEL - Free Report) and Adaptimmune Therapeutics plc . While Ligand sports a Zacks Rank #1 (Strong Buy), Exelixis and Adaptimmune carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up $3.68 to $3.70 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 6.19%. The share price of the company has increased 44% year to date.
Exelixis’ earnings per share estimates have moved up from 26 cents to 45 cents for 2017 and from 63 cents to 70 cents for 2018 over the last 30 days. The company delivered positive earnings surprises in all of the trailing four quarters, with an average beat of 572.92%. The share price of the company has increased 78.3% year to date.
Adaptimmune’s loss per share estimates have narrowed from 96 cents to 76 cents for 2017 and from 90 cents to 74 cents for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 24.79%. The share price of the company has increased 101.7% year to date.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
Agenus Inc. (AGEN - Free Report) incurred loss of 37 cents per share in line with the Zacks Consensus Estimate. The figure came in narrower the year-ago loss of 47 cents.
Revenues of $3.4 million missed the Zacks Consensus Estimate of $4 million. Also, the top line was down from $4.4 million in the year-ago quarter.
So far this year, shares of Agenus have declined 15.1%, as against the industry’s growth of 3.3%.
Quarterly Highlights
Agenus' third-quarter research and development (R&D) expenses were up 19.5% to $25.8 million. However, general and administrative expenses were down slightly by 0.7% to $8.1 million.
Pipeline Update
Agenus is progressing well with various candidates in its pipeline. The company expects to complete phase I dose-escalation, and generate safety and pharmacodynamic data for its anti-CTLA-4 antibody AGEN1884 later in 2017. Also, it is planning to start combination trials of AGEN1884 and AGEN2034 by the year end.
Agenus separate business entity -AgenTus, will help enhance business focus, speed and efficiency towards the realization of breakthrough immuno-oncology drugs designed to cure patients with advanced cancers.
Zacks Rank and Key Picks
Agenus carries a Zacks Rank #2 (Buy).Some other top-ranked health care stocks in the same space include Ligand Pharmaceuticals Inc. (LGND - Free Report) , Exelixis, Inc. (EXEL - Free Report) and Adaptimmune Therapeutics plc . While Ligand sports a Zacks Rank #1 (Strong Buy), Exelixis and Adaptimmune carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up $3.68 to $3.70 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 6.19%. The share price of the company has increased 44% year to date.
Exelixis’ earnings per share estimates have moved up from 26 cents to 45 cents for 2017 and from 63 cents to 70 cents for 2018 over the last 30 days. The company delivered positive earnings surprises in all of the trailing four quarters, with an average beat of 572.92%. The share price of the company has increased 78.3% year to date.
Adaptimmune’s loss per share estimates have narrowed from 96 cents to 76 cents for 2017 and from 90 cents to 74 cents for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 24.79%. The share price of the company has increased 101.7% year to date.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>